Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASAH1 | Q13510 | 1/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.38 |
| ▸ | HTR1A | P08908 | 5/20 | 0.38 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.38 |
| ▸ | NAAA | Q02083 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TK1 | P04183 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5409360 | 0.91 | ASAH1 (0.39) | ASAH1GMNNTP53POLBMAPT | |
| SCHEMBL5413262 | 0.88 | ASAH1 (0.41) | ASAH1GMNNTP53POLBMAPT | |
| SCHEMBL5408005 | 0.87 | ASAH1 (0.38) | ASAH1GMNNTP53POLBMAPT | |
| SCHEMBL24340370 | 0.85 | ASAH1 (0.58) | ASAH1CYP2C9HDAC6 | |
| SCHEMBL24340372 | 0.85 | ASAH1 (0.58) | ASAH1CYP2C9HDAC6 | |
| SCHEMBL9670603 | 0.81 | PLA2G4B (0.47) | GMNNTP53POLBMAPTTHRB | |
| SCHEMBL6346341 | 0.80 | EPHX2 (0.56) | ASAH1 | |
| SCHEMBL6346335 | 0.80 | EPHX2 (0.56) | ASAH1 | |
| SCHEMBL23373452 | 0.79 | ASAH1 (0.51) | ASAH1HDAC6 | |
| SCHEMBL5407492 | 0.77 | CES2 (0.53) | ASAH1GMNNTP53POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253296-B2 | Acylated aminopropanediols and analogues and therapeutic uses thereof | GENFIT (FR) | 2007-08-07 | — | — | US | disclosed |
| US-20060154984-A1 | Therapeutic use of acyl glycerols and the nitrogen- and sulphur- containing analogues thereof | GENFIT (FR) | 2006-07-13 | — | — | US | disclosed |
| US-20060069156-A1 | Acylated aminopropanediols and analogues and therapeutic uses thereof | GENFIT (FR) | 2006-03-30 | — | — | US | disclosed |
| US-20060035977-A1 | Uses of acylated aminopropanediols and sulphur and nitrogen analogues of same f | GENTIF (FR) | 2006-02-16 | — | — | US | disclosed |
| EP-1596845-A1 | THERAPEUTIC USE OF ACYL GLYCEROLS AND THE NITROGEN- AND SULPHUR-CONTAINING ANALOGUES THEROF | Genfit (FR) | 2005-11-23 | — | — | EP | disclosed |
| EP-1594486-A2 | USES OF ACYLATED AMINOPROPANEDIOLS AND SULPHUR AND NITROGEN ANALOGUES OF SAME | Genfit (FR) | 2005-11-16 | — | — | EP | disclosed |
| EP-1592660-A1 | ACYLATED AMINOPROPANEDIOLS AND ANALOGUES AND THERAPEUTIC USES THEREOF | Genfit (FR) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004073698-A1 | THERAPEUTIC USE OF ACYL GLYCEROLS AND THE NITROGEN- AND SULPHUR-CONTAINING ANALOGUES THEROF | GENFIT (FR) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004073593-A2 | USE OF ACYLATED AMINOPROPANEDIOLS AND SULPHUR AND NITROGEN ANALOGUES OF SAME FOR DIFFERENT THERAPEUTIC APPLICATIONS | GENFIT (FR) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004074239-A1 | ACYLATED AMINOPROPANEDIOLS AND ANALOGUES AND THERAPEUTIC USES THEREOF | GENFIT (FR) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069156-A1 | Acylated aminopropanediols and analogues and therapeutic uses thereof | AASDHPPT, ABAT, AADAC | ASAH1 409/4885GMNN 2989/4885TP53 3886/4885 |
| US-20060035977-A1 | Uses of acylated aminopropanediols and sulphur and nitrogen analogues of same f | ASS1, SMURF1, SMURF2 | ASAH1 307/4885GMNN 2879/4885TP53 937/4885 |
| US-20060154984-A1 | Therapeutic use of acyl glycerols and the nitrogen- and sulphur- containing analogues thereof | AGPAT5, HAGH, AGPAT2 | ASAH1 57/4885GMNN 574/4885TP53 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.